medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2016-10-140-142medsovet-1417Research ArticleУРОЛОГИЯUROLOGYЛечение гиперактивного мочевого пузыря: расширяем горизонтыTHERAPY OF HYPERACTIVE URINARY BLADDER: EXPANSION OF HORIZONSКАРПОВЕ. И.KARPOVE. I.

к.м.н.

Рязань

PhD in medicine

Ryazan

городская больница №6, медицинский центр «Гармония»РоссияMunicipal Hospital No.6, Medical Center GarmoniaRussian Federation201630122016010140142Copyright © КАРПОВ Е.И., 20162016КАРПОВ Е.И.KARPOV E.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/1417

Гиперактивный мочевой пузырь (ГАМП) – одно из наиболее частых расстройств мочеиспускания. Гиперактивный мочевой пузырь (ГАМП, ГМП) – синдром, характеризующийся наличием императивных позывов, сопровождающихся или несопровождающихся ургентным недержанием мочи обычно в сочетании с учащенным мочеиспусканием и ноктурией, при доказанном отсутствии инфекции или других явных патологических изменений. Фармакотерапия – приоритетный метод лечения ГАМП. Основной группой лекарственных средств являются м-холиноблокаторы (толтеродин, оксибутинин, троспия хлорид, солифенацин). Солифенацин – современный и эффективный препарат для лечения ГАМП, имеющий ограничения по показаниям, таким как закрытоугольная глаукома, задержка мочи, тяжелые желудочно-кишечные заболевания, миастения gravis. Мирабегрон – первый агонист β3-адренорецепторов для лечения ГАПМ, который подтвердил свою эффективность у пациентов, ранее получавших терапию м-холинолитиками. Мирабегрон можно применять при глаукоме и миастении, он не вызывает острую задержку мочи.

Hyperactive urinary bladder (HUB) is one of the most frequent disturbances of the urination. Hyperactive urinary bladder (HUB) is a syndrome characterized by presence of imperative uriesthesia accompanied and not accompanied by urgent urinary incontinence usually in combination with frequent urination and nocturia with proved lack of infection and other evident pathologic changes. Pharmacotherapy is a priority method of HUB therapy. The major group of drugs is m-cholinblockers (tolterodine, oxybutinine, trospium chloride, solifenacin). Solifenacin is a modern and effective drug for therapy of HUB that has limitations on indications such as closed- ngle glaucoma, retention of urine, grave gastrointestinal diseases, myasthenia gravis. Mirabegron is the first β3-adrenoreceptor antagonist for therapy of HUB that proved its effectiveness in patients ho previously received therapy by m-cholinolytics. Mirabegron can be used at glaucoma and myasthenia, it doesn’t cause acute urine retention.

гиперактивный мочевой пузырьсолифенацинмирабегронпобочные эффектыпротивопоказанияhyperactive urinary bladdersolifenacinmirabegronside effectscontraindicationsReferencesMilsom I, Abrams P, Cardoso L, et. al. How widespread are the symptoms of an overactive bladder and how are they managed? A population- based prevalence study. BJU Int, 2001, 87(9): 760-6.Milsom I, Abrams P, Cardoso L, et. al. How widespread are the symptoms of an overactive bladder and how are they managed? A population- based prevalence study. BJU Int, 2001, 87(9): 760-6.Гориловский М.Л., Лахно Д.А. Гиперактивность мочевого пузыря. РМЖ, 2005, 13(25): 1691-1694./Gorilovskiy M.L., Lakhno D.A. Hyperactivity of urinary bladder. RMZ, 2005, 13 (25): 1691-1694.Гориловский М.Л., Лахно Д.А. Гиперактивность мочевого пузыря. РМЖ, 2005, 13(25): 1691-1694./Gorilovskiy M.L., Lakhno D.A. Hyperactivity of urinary bladder. RMZ, 2005, 13 (25): 1691-1694.Verner P. Tolterodin – profile leciv. Farmakologie, 2005, 5: 464-469.Verner P. Tolterodin – profile leciv. Farmakologie, 2005, 5: 464-469.Irwin D.E.. Milsom I, Huskaar S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol, 2006, 50(6): 0306-14.Irwin D.E.. Milsom I, Huskaar S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol, 2006, 50(6): 0306-14.Abrams P. Describing bladder storage function: overactive bladder syndrome and detrusor overactivity. Urology, 2003, 62 (5 Suppl 2): 28-37, discussion 40-2.Abrams P. Describing bladder storage function: overactive bladder syndrome and detrusor overactivity. Urology, 2003, 62 (5 Suppl 2): 28-37, discussion 40-2.Abrams P, Artibani W, Cardoso L et. al. Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn, 2009, 28(4): 287.Abrams P, Artibani W, Cardoso L et. al. Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn, 2009, 28(4): 287.Клинические рекомендации Европейской ассоциации урологов, 2014. М., 2014. 968 с. / Clinical Recommendations of European Urologist Association, 2014. M., 2014, 968 p.Клинические рекомендации Европейской ассоциации урологов, 2014. М., 2014. 968 с. / Clinical Recommendations of European Urologist Association, 2014. M., 2014, 968 p.Гаджиева З.К. Нарушения мочеиспускания: руководство. Под ред. Ю.Г. Аляева. М.: ГЭОТАР-Медиа, 2010. 176 с. / Gadjieva Z.K. Disturbances of urination: Guidance. Ed. by Y.G. Alyaev. M.: GEOTARMedia, 2010,176 p.Гаджиева З.К. Нарушения мочеиспускания: руководство. Под ред. Ю.Г. Аляева. М.: ГЭОТАР-Медиа, 2010. 176 с. / Gadjieva Z.K. Disturbances of urination: Guidance. Ed. by Y.G. Alyaev. M.: GEOTARMedia, 2010,176 p.Benner JS, Nichol MB, Rovner ES et al. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int, 2010, 105(9): 1276-82.Benner JS, Nichol MB, Rovner ES et al. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int, 2010, 105(9): 1276-82.Compion G, Jackson J, Jenes J. Reasons for switching antimuscarinic therapy: Results from a European cross-sectional survey of physicians, and patients with OAB. Poster presented at the European Association of Urology Annual Meeting 2012. Poster 691.Compion G, Jackson J, Jenes J. Reasons for switching antimuscarinic therapy: Results from a European cross-sectional survey of physicians, and patients with OAB. Poster presented at the European Association of Urology Annual Meeting 2012. Poster 691.Khullar V, Amarenco G, Angulo J.C., et al. Efficacy and tolerability of mirabegron, a 3-adrenoreceptor agonist, in patients with overactive bladder: results from a randomized European-Australian Phase 3 Trial. Eur Urol, 2013, 63(2): 283-95.Khullar V, Amarenco G, Angulo J.C., et al. Efficacy and tolerability of mirabegron, a 3-adrenoreceptor agonist, in patients with overactive bladder: results from a randomized European-Australian Phase 3 Trial. Eur Urol, 2013, 63(2): 283-95.Novack GD, Lewis RA, Vogel R et al. Randomized, double-masked, placebo- controlled study to assess the ocular safety of mirabegron in healthy volunteers. J Ocul Pharmacol Ther, 2013 Apr 15, Epub ahead of print.Novack GD, Lewis RA, Vogel R et al. Randomized, double-masked, placebo- controlled study to assess the ocular safety of mirabegron in healthy volunteers. J Ocul Pharmacol Ther, 2013 Apr 15, Epub ahead of print.Astellas Pharma Europe Ltd. BetmigaTM Summary of Product Characteristics. January 2013.Astellas Pharma Europe Ltd. BetmigaTM Summary of Product Characteristics. January 2013.

The authors declare that there are no conflicts of interest present.